Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 24, 2023 08:58 ET | Source: Aerami Therapeutics Inc

Aerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary Hypertension

DURHAM, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
May 11, 2023 08:00 ET | Source: Aerami Therapeutics Inc

Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901 (Inhaled Imatinib) for Pulmonary Hypertension at the 2023 American Thoracic Society (ATS) International Conference

DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
February 23, 2023 09:00 ET | Source: Aerami Therapeutics Inc

Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress

Expansion of the AER-901 development program to include pulmonary hypertension associated with interstitial lung disease (PH-ILD) builds on the company’s existing program in pulmonary arterial...
June 16, 2022 09:00 ET | Source: Aerami Therapeutics Inc

Aerami Therapeutics Appoints Lisa Yañez as Chief Operating Officer

DURHAM, N.C., June 16, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the “Company”), a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and other...
December 07, 2021 08:35 ET | Source: Aerami Therapeutics Holdings, Inc.

Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company

New entity poised to accelerate the development of Aerami’s diverse pipeline ofnext-generation inhaled therapies AER-901, Aerami’s proprietary inhaled, nebulized formulation of imatinib, targeted to...